WEGOVY® FLEXTOUCH® 2.4mg (Italian)

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – Key Features and Benefits

Wegovy® FlexTouch® 2.4mg is the full maintenance dose of semaglutide used for long-term weight loss and cardiometabolic risk reduction. Administered once weekly, it acts on GLP-1 receptors in the brain to control appetite, helping patients sustain weight loss when combined with lifestyle changes.

• Active ingredient: Semaglutide (GLP-1 receptor agonist)

• Therapeutic dose: 2.4 mg weekly (maximum recommended)

• Primary function: Long-term weight management and appetite control

• Helps reduce:

  • Body weight

  • Food cravings

  • Risk of cardiovascular events in certain patients

• Form: Subcutaneous injection via pre-filled FlexTouch® pen (clear, colorless solution)

• Approved for:

  • Adults with BMI ≥30 or ≥27 with comorbidities

  • Adolescents ≥12 years, >60 kg, after demonstrating effectiveness

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – Indications

The 2.4 mg strength is the target maintenance dose used after 16 weeks of dose escalation. It is indicated for use in patients with obesity, overweight with complications, or cardiovascular risk.

• Adults:

  • BMI ≥30 kg/m² (obesity)

  • BMI 27–29.9 kg/m² (overweight with comorbidities)

  • BMI ≥27 kg/m² with a history of cardiovascular disease (even without diabetes)

• Adolescents (≥12 years):

  • With obesity and weight >60 kg

  • Continued use only if ≥5% BMI reduction after 12 weeks at 2.4 mg or maximum tolerated dose

• Not intended for:

  • Type 1 diabetes

  • Concurrent use with other weight loss medications

• Used alongside: Calorie reduction and increased physical activity

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – Ingredients

This formulation contains the highest dose of semaglutide available in the Wegovy® line, designed for long-term weekly use.

• Active ingredient:

  • Semaglutide: 3.2 mg/mL (9.6 mg in 3.0 mL total)

• Inactive ingredients:

  • Dibasic sodium phosphate dihydrate

  • Propylene glycol

  • Phenol

  • Water for injections

  • Sodium hydroxide/hydrochloric acid (for pH)

• Sodium content:

  • <23 mg per dose (considered sodium-free)

• Appearance: Clear, colorless solution in pre-filled pen

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – How To Use

Wegovy® 2.4 mg is injected once per week after a 16-week dose escalation. Patients should not exceed this dose, as it represents the maximum approved maintenance level.

• Route: Subcutaneous (abdomen, thigh, or upper arm)

• Frequency: Weekly, on the same day each week

• Dose escalation schedule (for new users):

  • Week 1–4: 0.25 mg

  • Week 5–8: 0.5 mg

  • Week 9–12: 1.0 mg

  • Week 13–16: 1.7 mg

  • Week 17+: 2.4 mg (maintenance dose)

• Pen contains: 9.6 mg of semaglutide (3.2 mg/mL in 3 mL) = 4 doses

• Missed dose:

  • If ≤5 days late: take ASAP

  • If >5 days late: skip and resume on next scheduled day

• Storage:

  • Keep refrigerated (2–8°C), or at room temp (<30°C) for up to 6 weeks

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – Side Effects

Side effects may increase with dose, particularly gastrointestinal symptoms. While most effects are temporary, serious reactions may occur and require medical attention.

Very common (≥1 in 10):

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Headache

• Abdominal pain

• Fatigue

Common (≤1 in 10):

• Dizziness

• Bloating, burping

• Indigestion, flatulence

• Dry mouth

• Gallstones

• Injection site reactions

Uncommon or serious:

• Acute pancreatitis: Persistent stomach/back pain

• Severe allergic reaction: Facial swelling, breathing difficulty, rash

• Bowel obstruction: Severe constipation, vomiting, bloating

• Retinopathy worsening in diabetics

• Hypoglycemia: Especially when combined with insulin or sulfonylureas

Hypoglycemia symptoms:

• Shaking, cold sweat

• Drowsiness or confusion

• Blurred vision

• Hunger, fast heartbeat

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – Clinical Studies

Wegovy® at the 2.4 mg dose is backed by multiple phase 3 clinical trials, which have demonstrated consistent long-term weight reduction and cardiometabolic benefit in both adults and adolescents.

• Study populations:

  • Adults with and without diabetes

  • Adolescents with obesity

• Key outcomes:

  • Average weight loss of 15–17% over 68 weeks in trials

  • Reduced incidence of major adverse cardiovascular events

• Adolescent requirement:

  • Must lose ≥5% of BMI after 12 weeks at 2.4 mg to continue

• Improvements noted in:

  • Waist circumference, HbA1c, blood pressure, and lipid profile

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – Manufacturer Information

Wegovy® is manufactured and distributed by Novo Nordisk, an established leader in endocrine and metabolic pharmaceuticals. They provide patient resources such as WegovyCare® in Australia.

• Manufacturer: Novo Nordisk A/S

• Distributor (Australia): Novo Nordisk Pharmaceuticals Pty. Ltd., North Sydney

• Distributor (New Zealand): Novo Nordisk Pharmaceuticals Ltd., Auckland

• Product code: Aust R 424394 (2.4 mg)

• Support program: https://wegovycare.com.au

• Official websites:

  • www.novonordisk.com.au

  • www.novonordisk.co.nz

WEGOVY® FLEXTOUCH® 2.4mg (ITALIAN) – FAQ

What is Wegovy® 2.4 mg used for?
This is the full therapeutic dose used for long-term weight loss and to reduce cardiovascular risks in adults with obesity or high BMI and heart disease.

How long can I use Wegovy® 2.4 mg?
It can be used indefinitely under medical supervision, as long as it remains effective and well-tolerated.

Does Wegovy® 2.4 mg really work?
Yes, clinical trials showed average weight loss of 15% or more when paired with diet and exercise.

Can Wegovy® 2.4 mg be taken with food?
Yes, it can be taken any time of day, regardless of meals.

Can I stay on 2.4 mg permanently?
Yes, this is the maintenance dose. Do not exceed it. Your doctor will reassess your progress periodically.

What if I can’t tolerate 2.4 mg?
Some patients may stay on the maximum tolerated dose (e.g. 1.7 mg) if 2.4 mg causes persistent side effects.

Can adolescents take 2.4 mg Wegovy®?
Yes, but only if aged ≥12 years, body weight >60 kg, and if ≥5% BMI loss is seen after 12 weeks at full dose.